Chimerix (NASDAQ:CMRX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $11.00 price objective on the biopharmaceutical company’s stock.

Separately, Wedbush reiterated an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Trading Up 10.0 %

NASDAQ:CMRX opened at $4.82 on Tuesday. The firm has a market capitalization of $433.42 million, a price-to-earnings ratio of -5.13 and a beta of 0.35. The firm’s fifty day simple moving average is $3.64 and its 200 day simple moving average is $1.88. Chimerix has a twelve month low of $0.75 and a twelve month high of $5.15.

Insider Transactions at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company’s stock, valued at $2,755,405.56. This represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. lifted its stake in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after purchasing an additional 496,823 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in Chimerix during the fourth quarter valued at approximately $2,626,000. Valeo Financial Advisors LLC raised its holdings in shares of Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after acquiring an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Chimerix during the fourth quarter valued at approximately $221,000. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.